

7 December 2012

Centralised Company Announcements Platform Australian Stock Exchange 10th floor, 20 Bond Street Sydney NSW 2000

Dear Sir / Madam,

### Appendix 3B – Issue of Shares

The Board of Directors of Allied Healthcare Group Ltd (ASX: AHZ) hereby announces that the Company has allotted 3,617,355 shares each at a deemed issue price of \$0.0229 (based on a 5 day VWAP at 5 December 2012) to directors in lieu of directors fees as agreed by shareholders in Resolutions 4 to 6 at the Annual General Meeting. The Board of Directors also announces 13 ordinary shares have been allotted upon the clearing of receipts totalling \$1.30 on exercise of 13 options exercisable at \$0.10

Refer to the attached Appendix 3B

Yours sincerely

For and on behalf of Allied Healthcare Group Limited

Stephen Mann

**Company Secretary** 



ABN 35 088 221 078 Level 1, 197 Adelaide Terrace Perth Western Australia 6000

PO Box 6879 East Perth Western Australia 6892

T+61 (0) 8 9385 5038 F+61 (0) 8 9385 5028 E info@alliedhealthcaregroup.com.au www.alliedhealthcaregroup.com.au

070033Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity	
ALLIED HEALTHCARE GROUP LIMI	TED
ABN	
35 088 221 078	

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Ordinary shares fully paid

- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (a) 3,617,355
- (b) 13
- 3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- (a) & (b) Ordinary shares fully paid ranking equally with existing ordinary shares fully paid.

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
5	Issue price or consideration	(a) Deemed issued price of \$0.0229 per share (based on a 5 day VWAP at 5/12/12) (Total \$82,788.36) (b) \$0.10 per option exercised (Total \$1.30)	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>(a) Issued to directors in lieu of directors fees as agreed by shareholders in Resolutions 4 to 6 at the Annual General Meeting)</li> <li>(b) Exercise of unlisted \$0.10 options exp 31/12/2012</li> </ul>	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	6 December 2012	
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)	805,362,681	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
5,800,000	18/05/17
	\$0.06 options
7,400,000	10/07/16 \$0.06 options
53,600,000	10/07/16
	\$0.06 options
5,000,000	22/10/14
3,000,000	\$0.10 options
	7 v r
6,000,000	20/10/14
	\$0.06 options
200 150	31/12/12
209,159	\$0.10 options
	φυ. το ορασίις

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

# Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	NA
21	Amount of any underwriting fee or	NA
	commission	
2.2		
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the	N/A
	broker to the issue	
24	Amount of any handling fee	NA
	payable to brokers who lodge	
	acceptances or renunciations on behalf of *security holders	
	benan or security noiders	
25	If the issue is contingent on	NA
	+security holders' approval, the date	
	of the meeting	
26	Date entitlement and acceptance	N/A
	form and prospectus or Product Disclosure Statement will be sent to	
	persons entitled	
	persons entitied	
27	If the entity has issued options, and	N/A
	the terms entitle option holders to	
	participate on exercise, the date on	
	which notices will be sent to option	
	holders	
28	Date rights trading will begin (if	N/A
20	applicable)	11/13
	applicate)	
29	Date rights trading will end (if	NA
	applicable)	
30	How do +security holders sell their	NA
50	entitlements in full through a	IVA
	broker?	
31	How do +security holders sell part	NA
	of their entitlements through a	
	broker and accept for the balance?	

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do +security holders dispose ir entitlements (except by sale th a broker)?	NA
33	+Desp	atch date	N/A
	1		
Daw			4:
		Quotation of security omplete this section if you are apple	
			ying for quounton of securities
34	Type (tick o	of securities one)	
(a)		Securities described in Part 1	
(b)		All other securities	
			of the escrowed period, partly paid securities that become fully paid, employee ends, securities issued on expiry or conversion of convertible securities
Enti	ities	that have ticked bo	x 34(a)
Add	itiona	al securities forming a	new class of securities
Tick to		e you are providing the informat	ion or
35		_ · ·	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by
		NA	
36			y securities, a distribution schedule of the additional ber of holders in the categories
		NA	
37		A copy of any trust deed for the	ne additional *securities
		N/A	

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	N/A	N/A

<sup>+</sup> See chapter 19 for defined terms.

# **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any
  applications received by us in relation to any +securities to be quoted and that noone has any right to return any +securities to be quoted under sections 737, 738 or
  1016F of the Corporations Act at the time that we request that the +securities be
  quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 7 December 2012

Company Secretary

Print name: Stephen Mann

<sup>+</sup> See chapter 19 for defined terms.